Shots:
- HMNC & Spruce has dosed the first pts with tildacerfont in P-II (TAMARIND) trial for the treatment of major depressive disorder (MDD)
- The P-II (TAMARIND) trial will assess tildacerfont vs PBO in 88 MDD adults across the UK for an 8wk. treatment period followed by a 4wk. follow-up period to evaluate change in Hamilton Depression Rating Scale scores as 1EP, while 2EPs incl. changes in functional impairment per Sheehan Disability Scale, response, remission, & overall QoL; topline data is expected in H1’26
- Tildacerfont is a CRF1 receptor antagonist that blocks the action of hypothalamic CRF to potentially normalize HPA axis dysfunction & overactive CRF signaling in MDD pts
Ref: GlobeNewsWire | Image: HMNC Brain Health and Spruce Biosciences| Press Release
Related News:- Sun Pharma Reports Topline Data from P-III (INSPIRE-1 & INSPIRE-2) Trials of Ilumya (Tildrakizumab) for Active Psoriatic Arthritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
